• Avricore Health (AVCR) has announced an agreement to pilot its HealthTab platform for diabetes patients in select Shoppers Drug Mart pharmacies
  • The overarching goal of HealthTab is to reduce the negative health impacts and ensure those living with diabetes can have a high quality of life
  • The program will launch in 11 Shoppers Drug Mart locations in the province of Ontario 
  • The initial focus of the program will be screening patients who are at risk for developing diabetes and cardiovascular conditions
  • It will also support those who are already living with diabetes 
  • Shares of Avricore Health are down 2.50 per cent, trading at C$0.20

Avricore Health announced it has signed a master agreement with Shoppers Drug Mart pharmacies to pilot its HealthTab platform in managing diabetes.

The pilot program will roll out across 11 Shoppers Drug Mart locations in the province of Ontario and will initially focus on screening patients who are at risk for developing diabetes and cardiovascular conditions. It will also aim to support patients who have already been diagnosed with diabetes by helping them manage their symptoms and live a higher quality of life.

According to the press release, the pilot pharmacists will test a patient’s average blood sugar and lipids while results will be reported through the company’s cloud-based HealthTab system.

“Having accessible, high-quality diagnostics with real-time data reporting and the support of a trusted Shoppers Drug Mart pharmacist is a powerful combination in the battle against chronic disease in Canada,” Hector Bremner, CEO of Avricore Health, said in a press release. “This initiative is a major step forward for our mission to deliver the most accessible early disease detection and management platform in the country.”

The HealthTab platform is a point-of-care screening system that only requires just a few drops of blood from a finger prick. Results can then be printed in-store or accessed online.

Shares of Avricore Health are down 2.50 per cent to C$0.20.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.